Program 18 : Digestive Cancers

Program 18 : Digestive Cancers

PROGRAM LEADERS

Pr Thomas APARICIO, is leader of Digestive Oncology at Saint-Louis Hospital, Professor of Medicine at University of Paris-Cité, medical director of medico-universitary department ICARE regrouping 11 oncology, surgery and inflammatory units. Member of the research team « intestinal Immunity in Inflammation and Cancer », INSERM 1160 at Institut de Recherche Saint Louis. He is the present president of the Fédération Francophone de Cancérology Digestive (FFCD), the main French research group on digestive oncology; He’s mains topic are oesogastric cancer, colorectal cancer, small bowel adenocarcinoma, oncogeriatry and immunotherapy. SIGAPS score: 2146 ; h-index: 41

Pr Vinciane REBOURS, MD, PhD, is head of the Pancreatology and Digestive Oncology Department at Beaujon Hospital. She is Professor of Medicine at Université Paris Cité. She is leading the first center for pancreatic diseases in France (inflammatory and tumoral diseases). The department is labeled as European center of excellence for neuroendocrine tumors. She is member of the INSERM UMR1149, team 9 « From inflammation to digestive cancers ». She was president of the European Pancreatic Club and the French Society of Gastroenterology. Her main topics of research are the relation between inflammation and pancreatic cancer and precancerous lesions. »

HEALTHCARE EXECUTIVE

Isabelle ABITBOL

P18 - Digestive Cancers

STRENGTHS IN THE FOLLOWING AREAS

Cancer Care:

Our Institute is one of the most important French centers in digestive cancers care, with more than 2,000 new patients yearly, five hospitals with digestive surgery and hepato-gastro-enterology departments, covering a vast region of more than 5 million inhabitants, the great Paris north area. At Lariboisière and St-Louis Hospitals, the topics of excellence are esophageal-gastric cancers, colorectal cancers, primitive peritoneal cancers and rare small intestine cancers. At Bichat Hospital, colorectal cancer patients represent the larger activity. At Beaujon Hospital, the main areas are pancreas cancers, cholangiocarcinomas and hepatocarcinomas. Since 2009, it is the European reference center for digestive neuro-endocrine tumors (European Network EURANETS and labelled “center of excellence”). Finally, Louis Mourier Hospital’s activity is essentially colorectal cancers. All kind of surgery techniques are available at our Institute, as well as all interventional techniques, either endoscopic (biliary prosthesis, echo-endoscopy) or computed tomography (CT) guided (radio-embolization, radiofrequency, cryotherapy, hepatic intra-arterial chemotherapy). Beaujon Hospital is an expert center in radiomic studies in hepatocarcinomas with a dedicated basic research unit, a dedicated research hospital, and University multidisciplinary program (RHU MOSAIC). Genomics routine diagnosis (DNA NGS and RNAseq) is available onsite with two large molecular biology and genetic platforms at St-Louis and Bichat Hospitals respectively, with monthly molecular multidisciplinary tumor boards (MTB) at both sites, taking into account the large volume of analyses. A dedicated unit for hepatic transplantation is available for some patients with hepatic cancer at Beaujon Hospital. A dedicated oncogenetics team is available for counseling and follow-up of patients and families with hereditary gene alterations susceptibility. The clinical research activity is important with phase I to III trials and an active participation to National groups (PRODIGE/FFCD groups) as well as European groups (EURANETS, EORTC). Pr. T. Aparicio is currently the chair of the FFCD group of digestive cancers clinical research, sponsor of most of the academic large French clinical trials and chairs the GCO organization gathering all academic cooperative cancer groups labelled by the French NCI (INCa).

Research:

  • FHU MOSAIC :Multiscale Optimized Strategy for Artificial Intelligence based Imaging Biomarkers in Digestive Cancer (TNE) – L. de Mestier –V. Rebours
  • MOSAIC-MIDAS-NET: Molecular and imagomic characterization of avid F-DOPA intestinal NETs – L. de Mestier
  • INCA – Plan d’action intégré à la recherche : Early phases of pancreatic cancer associated with obesity and metabolic syndrome: tools for prevention and screening – Pr. Couvelard – Pr. Rebours

Basic science:

  • INSERM UMR1149- Inflammation Research Center – Team 9 : « From inflammation to cancers in digestive diseases »
  • INSERM UMR1149 – Imaging Biomarkers Laboratory
  • INSERM UMR1149 – Plasticity of gastro-intestinal mucosa in nutritional pathologies and after surgery
  • INSERM UMR 1160  Saint Louis Research Center : “Inflammation and digestive cancer team”

Education:

Our local medical leaders actively participate to education in each annual meeting of FFCD for digestive cancers. Pr. T. Aparicio is the coordinator of the residentship program of digestive oncology in the Ile-de-France region and participates to five university national courses in digestive oncology. He is associate editor of several journals: Digestive and Liver Disease (IF: 4.088), Journal of Geriatric Oncology (IF: 3.599), and Journal d’Oncogériatrie. Pr. V. Rebours also participates to four university teaching programs mainly dedicated to pancreas cancer and digestive epithelium biology. She is the chair of the European Pancreatic club, and the elected president of the French Society of Hepato-gastro-enterology. She is associate editor for the Pancreatology (IF: 3.996) journal. Pr. P. Ruszniewski is the dean of the Université Paris Cité medical faculty, and the Head of the European Neuroendocrine Tumor Society (ENETs) Center of excellence, while also coordinating the Ile-de-France Nord center from the national network of Neuro-endocrine tumors (RENATEN). He is also in charge of the education module of ESMO “theranostics in NETs” while being associate editor of the Neuroendocrinology journal.

JOURNEES PROFESSIONNELLES

3ème Journée d’oncologie digestive médico-chirurgicale : Cancer du rectum – questions actuelles

>>> Retrouvez toutes les présentations ICI